ArticleDiabetology & metabolic syndrome2025
Impact of elevated glucose levels on cardiac function in STEMI patients: glucose delta as a prognostic biomarker.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study.Cardiovascular diabetology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundElevated glucose levels have emerged as a significant prognostic factor following acute myocardial infarction (AMI).
objectiveThis study aimed to evaluate glycemic parameters associated with infarct size and left ventricular function. RESEARCH DESIGN AND
methodsA total of 244 patients with ST-segment elevation myocardial infarction (STEMI) treated using a pharmacoinvasive strategy were included. Glucose delta was calculated as the difference between mean glucose levels estimated from glycated hemoglobin (HbA1c) and serum glucose levels collected at hospital admission. Infarct size and left ventricular ejection fraction (LVEF) were assessed 30 days post-infarction using cardiac magnetic resonance (CMR) imaging.
resultsHigher glucose delta values were significantly associated with reduced LVEF and larger infarct size, regardless of diabetes diagnosis. Differences in infarcted ventricular mass were noted between diabetic and non-diabetic patients above specific thresholds: (18.62 ± 11.0 g) vs. (16.24 ± 13.17 g), p = 0.019, with an effect size of 0.55. The receiver operating characteristic curve yielded an area under the curve (AUC) of 0.65 (95% CI 0.57-0.72).
conclusionsIn STEMI patients undergoing pharmacoinvasive treatment, a higher glycemic delta was associated with greater infarct size and lower LVEF. This straightforward glycemic parameter provides valuable prognostic insight for both diabetic and non-diabetic populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.